Differential Effects of Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in Apolipoprotein E–Deficient Mice

R. Elhage, PhD; A. Maret, PhD; M.-T. Pieraggi, MD, PhD; J.C. Thiers, PhD; J.F. Arnal, MD, PhD; F. Bayard, MD, PhD

**Background**—The cytokines interleukin 1 (IL-1) and tumor necrosis factor (TNF) are secreted by the different cell populations of the vascular wall and have been suggested to promote atherosclerosis.

**Methods and Results**—Their respective roles in fatty-streak formation in apolipoprotein E–deficient mice were investigated by use of IL-1 receptor antagonist and TNF binding protein. Estradiol-17β was used as a positive control. Blocking TNF seemed to be active in female animals but not in males. IL-1 receptor antagonist was as effective as or more effective than estradiol in both sexes.

**Conclusions**—IL-1 plays a crucial role in the initial step of the atherosclerotic process in this animal model, and blocking the activity of this cytokine should be considered as a therapeutic possibility. (Circulation. 1998;97:242-244.)

**Key Words:** atherosclerosis ■ apolipoproteins ■ interleukins ■ tumor necrosis factor

It is known that IL-1α and -1β and TNF-α and -β are secreted in the vascular wall by endothelial and smooth muscle cells as well as by monocytes/macrophages. These cytokines have been shown to increase permeability of the endothelial cell barrier, induce the expression of surface leukocyte adhesion molecules, and enhance the production of other cytokines and growth factors, such as IL-6 and macrophage colony-stimulating factor, all such activities being considered to promote atherosclerosis. The objective of the present study was therefore to clarify the role of IL-1 and TNF in the initial steps of the atherosclerotic process, ie, fatty-streak formation, using apo E KO mice as an animal model of atherosclerosis and human IL-1ra and TNFbp as the specific cytokine antagonists. IL-1ra is a recombinant 17-kD protein, which binds to IL-1 receptors and competes with both IL-1α and IL-1β without detectable IL-1 agonistic effects. TNFbp is a specific TNF inhibitor consisting of two molecules of the extracellular domain of the human type 1 TNF receptor added to both ends of a molecule of polyethylene glycol. TNFbp binds with equal affinity to TNF-α and TNF-β. E2 treatment was used as a positive control, because we and others have shown that this hormone prevents fatty-streak formation in the apo E KO mouse animal model. The data obtained showed that TNFbp was active in female animals but not in males. Like E2, IL-1ra was active in both sexes, suggesting that IL-1 plays a crucial role in the initial step of the atherosclerotic process in this animal model.

**Methods**

**Study Protocol**

Apo E KO mice, originally obtained from the Jackson Laboratory, Bar Harbor, Me (sixth generation of backcross from 129/B6 F1 heterozygous to C57BL/6), were housed as previously described and fed normal laboratory mouse chow containing 4.3% fat and 0.02% cholesterol. Four-week-old animals were gonadectomized under general anesthesia. At 2 months of age, these animals were given 0.2 mg 60-day time-release E2 pellets (Innovative Research of America), a dose that was found to exert a maximal effect on fatty-streak formation, or placebo pellets associated with human IL-1ra treatment (25 mg kg body wt · d−1), human TNFbp (1 mg kg body wt · d−1), or BSA (25 mg kg body wt · d−1). IL-1ra and TNFbp were kindly provided by Amgen Inc. IL-1ra was administered by Alzet 2004 osmotic minipumps (Alza Inc) implanted in a dorsal subcutaneous pocket. TNFbp or BSA was injected subcutaneously every other day. When mice were 2 months of age, to accelerate the atherosclerotic process, a pelleted “atherogenic” diet containing 16% (wt/wt) fat (primary cocoa butter), 1.16% cholesterol, and 0.5% cholic acid was also given to all animals until they were euthanized at 3 months old. TNFbp- or BSA-treated animals were killed 24 hours after the last subcutaneous injection. All experimental protocols were performed in accordance with the recommendations of the French Accreditation of Laboratory Animal Care.

**Analytical Measurements**

The conditions of lipid analysis, evaluation of serum hormone concentrations, and fatty-streak lesions have been described.

Cellular composition was appreciated by immunohistochemistry using the monoclonal rat anti-mouse MOMA-2 antigen (SEROtec) and the monoclonal mouse anti-α-actin immunoglobulin (DAKO SA).
Serum levels of human IL-1ra and TNFbp were measured at the end of the treatment period with specific ELISAs (R&D Systems Europe Ltd).

Statistics

Results are expressed as mean±SEM. To test the respective roles of treatments and sex on the development of lesion areas, a two-way ANOVA was carried out after logarithmic transformation to take into account the positive skewness of their distribution. The specific action of each treatment in each sex was then tested by an unpaired t test. Bonferroni’s levels of significance were used to make allowance for multiple comparisons.

Results

Effect of In Vivo Treatment With E2, IL-1ra, and TNFbp on General Status and Lipids in Apo E KO Mice

At the time of euthanasia, the body weights were lower in this series of experiments (Table 1) than in our previous study of animals of the same age. Administration of the atherogenic diet may explain this difference, which concerned control as well as treated animals. None of the mice exhibited side effects caused by administration of IL-1ra or TNFbp. Human IL-1ra and TNFbp were not detectable in the sera of E2- or BSA-treated mice (Table 1). The serum concentrations of IL-1ra were within the range of those reported previously by Kitazawa et al but a log range higher for TNFbp concentrations measured 24 hours after the last injection. Moreover, a large scatter of the individual concentrations was observed, which probably reflected the emptying of the IL-1ra osmotic minipumps after 1 month of delivery. No clear explanation showed that under all three treatments and despite the difference in lesion size, the cellular composition of the lesions, macrophages, and smooth muscle cells appeared similar to those of castrated BSA-treated animals (data not shown).

Discussion

The most important finding of this study was the demonstration that specific antagonism of IL-1 activity was as effective as or more effective than E2 in reducing fatty-streak formation in both male and female apo E KO mice, without evident interference with lipid metabolism. This suggests a crucial role of IL-1 during the initial step of the atherosclerotic process. Despite comparable serum concentrations, TNFbp was less effective in female animals and was inactive in males, suggesting that the potency of IL-1ra was superior to that of TNFbp. These data should be interpreted with caution, because of the respective sizes and structures of the two antagonists or the

<table>
<thead>
<tr>
<th>TABLE 1. Effects of BSA, E2, IL-1ra, and TNFbp Treatment on Body Weight, Serum E2, Total Cholesterol, and Lesion Area in Castrated Female Mice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BSA (n=7)</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Body weight, g</td>
</tr>
<tr>
<td>E2, pg/mL</td>
</tr>
<tr>
<td>Uterine weight, mg</td>
</tr>
<tr>
<td>IL-1ra, µg/mL</td>
</tr>
<tr>
<td>TNFbp, µg/mL</td>
</tr>
<tr>
<td>Total cholesterol, g/L</td>
</tr>
<tr>
<td>Lesion area, mm²</td>
</tr>
</tbody>
</table>

n indicates number of animals studied; ND, not detectable. Results are mean±SEM.

*Statistically different from BSA-treated animals after logarithmic transformation.
possible development of antibodies to human TNFbp. Compared with our previous studies, the use of an atherogenic diet may have evidenced this sex difference in TNFbp effectiveness by revealing the female tendency to develop extensive lesions, which was not apparent with a chow diet. Current knowledge of plasma TNF concentrations or the function of TNF ligand and receptor families does not provide an explanation for this unexpected difference. Further studies are warranted, including time course and dose-response analysis, which could not be done in the present study because of shortage of the inhibitors, to determine the molecular and cellular mechanisms involved. The relevance of these observations in relation to sexually dimorphic immune responsiveness will also have to be clarified, but observations of accelerated fatty-streak development in mice deficient in p55 TNF receptor and future studies in TNF-, lymphotoxin-, or p55/p75 TNF receptor–deficient mice should take sex into consideration in the analysis of the data.

In conclusion, TNF in females and IL-1 in both sexes appear to play a crucial role in the constitution of fatty-streak lesions, the initial step of the atherosclerotic process, in the apolipoprotein E–deficient mouse model. Blocking the activity of these cytokines, especially IL-1, should now be considered as a therapeutic possibility.

Acknowledgments

This work was supported by INSERM/MSD and the Conseil Régional Midi-Pyrénées. Dr Elhage was supported by a grant from the Groupe de Rédaction sur la Recherche Cardiovasculaire. We thank Amgen Inc for its invaluable assistance by generously providing us with IL-1ra and TNFbp and D.J.P. Charette for statistical analysis.

References


TABLE 2. Effects of BSA, E₂, IL-1ra, and TNFbp Treatment on Body Weight, Serum E₂, Total Cholesterol, and Lesion Area in Castrated Male Mice

<table>
<thead>
<tr>
<th></th>
<th>BSA (n=6)</th>
<th>E₂ (n=4)</th>
<th>IL-1ra (n=6)</th>
<th>TNFbp (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight, g</td>
<td>17.4±0.8</td>
<td>19.2±0.7</td>
<td>18.8±0.9</td>
<td>17.9±0.7</td>
</tr>
<tr>
<td>E₂, pg/mL</td>
<td>ND</td>
<td>252±45</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>IL-1ra, µg/mL</td>
<td>ND</td>
<td>ND</td>
<td>1.1±0.5</td>
<td>ND</td>
</tr>
<tr>
<td>TNFbp, µg/mL</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>0.54±0.23</td>
</tr>
<tr>
<td>Total cholesterol, g/L</td>
<td>33.5±0.9</td>
<td>26.9±3.8</td>
<td>28.8±3.0</td>
<td>34.8±1.7</td>
</tr>
<tr>
<td>Lesion area, µm²</td>
<td>152.34±21.77</td>
<td>86.18±10.518</td>
<td>66.744±4267*</td>
<td>151.209±21.740</td>
</tr>
</tbody>
</table>

n indicates number of animals studied; ND, not detectable. Results are mean±SEM.

*Statistically different from BSA-treated animals after logarithmic transformation.
Differential Effects of Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in Apolipoprotein E–Deficient Mice

R. Elhage, A. Maret, M.-T. Pieraggi, J. C. Thiers, J. F. Arnal and F. Bayard

_Circulation_. 1998;97:242-244
doi: 10.1161/01.CIR.97.3.242
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1998 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/97/3/242

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/